45 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics plc
2 Aug 24
Approved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy
7:00am
community. HCPs can begin testing patients, Adaptimmune systems are ready to take TECELRA orders, and an integrated support program, AdaptimmuneAssist … for this patient community.”
Sandra D’Angelo, MD, Sarcoma Medical Oncologist and Cell Therapist, Memorial Sloan Kettering Cancer Center; SPEARHEAD Trial
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics plc
15 May 24
Adaptimmune Reports Q1 2024 Financial and Business Updates
7:39am
a live webcast at 8:00 a.m. EDT (1:00 p.m. BST) today.
Adrian Rawcliffe, Adaptimmune’s Chief Executive Officer: “Support from the sarcoma community
8-K
EX-99.1
eo1n0
6 Dec 23
Other Events
7:13am
8-K
EX-10.3
k1e g7blds6i36
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.4
shqyddvdiyopqcr2fjm
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.2
iwu or9bhpmz78b
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.2
7uil7emc1 mla1
18 Feb 20
Adaptimmune Announces Appointment of Gavin Wood as Chief Financial Officer
8:07am
8-K
EX-10.3
0k44q3 9yu34h01ueawe
18 Feb 20
Adaptimmune Announces Appointment of Gavin Wood as Chief Financial Officer
8:07am